Targeting the tumor microenvironment

References

• Darnell JE Jr.. STATs and gene regulation. Science 1997; 277:1630 - 5; http://dx.doi.org/10.1126/science.277.5332.1630; PMID: 9287210
   PubMed Web of Science ®Google Scholar
• Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109:1139 - 42; PMID: 11994401
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4:97 - 105; http://dx.doi.org/10.1038/nrc1275; PMID: 14964307
   PubMed Web of Science ®Google Scholar
• Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, et al. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem 2012; 287:13743 - 51; http://dx.doi.org/10.1074/jbc.M111.349167; PMID: 22523320
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A 2007; 104:4060 - 4; http://dx.doi.org/10.1073/pnas.0611665104; PMID: 17360477
   PubMed Web of Science ®Google Scholar
• He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 2003; 100:14133 - 8; http://dx.doi.org/10.1073/pnas.2232790100; PMID: 14617776
   PubMed Web of Science ®Google Scholar
• Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366:1905 - 13; http://dx.doi.org/10.1056/NEJMoa1114885; PMID: 22591296
   PubMed Web of Science ®Google Scholar
• Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7:673 - 83; http://dx.doi.org/10.1038/nrc2210; PMID: 17721432
   PubMed Web of Science ®Google Scholar
• Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007; 9:R32; http://dx.doi.org/10.1186/bcr1680; PMID: 17531096
   PubMed Web of Science ®Google Scholar
• Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007; 117:3660 - 3; http://dx.doi.org/10.1172/JCI34237; PMID: 18060028
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15:103 - 13; http://dx.doi.org/10.1016/j.ccr.2009.01.001; PMID: 19185845
   PubMed Web of Science ®Google Scholar
• Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16:1421 - 8; http://dx.doi.org/10.1038/nm.2250; PMID: 21102457
   PubMed Web of Science ®Google Scholar
• Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007; 21:1714 - 9; http://dx.doi.org/10.1101/gad.1549407; PMID: 17639077
   PubMed Web of Science ®Google Scholar
• Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117:3846 - 56; http://dx.doi.org/10.1172/JCI31871; PMID: 18060032
   PubMed Web of Science ®Google Scholar
• Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003; 63:2948 - 56; PMID: 12782602
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3:900 - 11; http://dx.doi.org/10.1038/nri1226; PMID: 14668806
   PubMed Web of Science ®Google Scholar
• Stark GR, Darnell JE Jr.. The JAK-STAT pathway at twenty. Immunity 2012; 36:503 - 14; http://dx.doi.org/10.1016/j.immuni.2012.03.013; PMID: 22520844
   PubMed Web of Science ®Google Scholar
• Kim DJ, Tremblay ML, Digiovanni J. Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS One 2010; 5:e10290; http://dx.doi.org/10.1371/journal.pone.0010290; PMID: 20421975
   PubMed Web of Science ®Google Scholar
• Sekine Y, Tsuji S, Ikeda O, Sato N, Aoki N, Aoyama K, et al. Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene 2006; 25:5801 - 6; http://dx.doi.org/10.1038/sj.onc.1209578; PMID: 16636663
   PubMed Web of Science ®Google Scholar
• Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer - more than a “gut” feeling?. Cell Div 2010; 5:14; http://dx.doi.org/10.1186/1747-1028-5-14; PMID: 20478049
   PubMed Web of Science ®Google Scholar
• Braun DA, Fribourg M, Sealfon SC. Cytokine response is determined by duration of receptor and STAT3 activation. J Biol Chem 2012; 288:2986 - 93; http://dx.doi.org/10.1074/jbc.M112.386573; PMID: 23166328
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98:295 - 303; http://dx.doi.org/10.1016/S0092-8674(00)81959-5; PMID: 10458605
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41 - 51; http://dx.doi.org/10.1038/nri1995; PMID: 17186030
   PubMed Web of Science ®Google Scholar
• Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118:3367 - 77; http://dx.doi.org/10.1172/JCI35213; PMID: 18776941
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139:693 - 706; http://dx.doi.org/10.1016/j.cell.2009.10.014; PMID: 19878981
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39:493 - 506; http://dx.doi.org/10.1016/j.molcel.2010.07.023; PMID: 20797623
   PubMed Web of Science ®Google Scholar
• Rokavec M, Wu W, Luo JL. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 2012; 45:777 - 89; http://dx.doi.org/10.1016/j.molcel.2012.01.015; PMID: 22364742
   PubMed Web of Science ®Google Scholar
• Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 2007; 67:8494 - 503; http://dx.doi.org/10.1158/0008-5472.CAN-07-0647; PMID: 17875688
   PubMed Web of Science ®Google Scholar
• Ho PL, Lay EJ, Jian W, Parra D, Chan KS. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 2012; 72:3135 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-11-3195; PMID: 22532166
   PubMed Web of Science ®Google Scholar
• Kim DJ, Angel JM, Sano S, DiGiovanni J. Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. Oncogene 2009; 28:950 - 60; http://dx.doi.org/10.1038/onc.2008.453; PMID: 19137019
   PubMed Web of Science ®Google Scholar
• Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010; 70:2558 - 67; http://dx.doi.org/10.1158/0008-5472.CAN-09-2840; PMID: 20215508
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8:1089 - 97; http://dx.doi.org/10.1038/nm763; PMID: 12219085
   PubMed Web of Science ®Google Scholar
• Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 2009; 69:6823 - 30; http://dx.doi.org/10.1158/0008-5472.CAN-09-1684; PMID: 19690134
   PubMed Web of Science ®Google Scholar
• Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15:79 - 80; http://dx.doi.org/10.1016/j.ccr.2009.01.009; PMID: 19185839
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 2011; 71:5020 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-11-0908; PMID: 21586612
   PubMed Web of Science ®Google Scholar
• Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011; 19:441 - 55; http://dx.doi.org/10.1016/j.ccr.2011.03.002; PMID: 21481787
   PubMed Web of Science ®Google Scholar
• Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 2011; 71:6601 - 10; http://dx.doi.org/10.1158/0008-5472.CAN-11-1217; PMID: 21920898
   PubMed Web of Science ®Google Scholar
• Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16:487 - 97; http://dx.doi.org/10.1016/j.ccr.2009.10.015; PMID: 19962667
   PubMed Web of Science ®Google Scholar
• Azare J, Doane A, Leslie K, Chang Q, Berishaj M, Nnoli J, et al. Stat3 mediates expression of autotaxin in breast cancer. PLoS One 2011; 6:e27851; http://dx.doi.org/10.1371/journal.pone.0027851; PMID: 22140473
   PubMed Web of Science ®Google Scholar
• Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008; 68:9087 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-08-0400; PMID: 18974155
   PubMed Web of Science ®Google Scholar
• Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117:3988 - 4002; http://dx.doi.org/10.1172/JCI32533; PMID: 18060036
   PubMed Web of Science ®Google Scholar
• Walter M, Liang S, Ghosh S, Hornsby PJ, Li R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 2009; 28:2745 - 55; http://dx.doi.org/10.1038/onc.2009.130; PMID: 19483720
   PubMed Web of Science ®Google Scholar
• Lederle W, Depner S, Schnur S, Obermueller E, Catone N, Just A, et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int J Cancer 2011; 128:2803 - 14; http://dx.doi.org/10.1002/ijc.25621; PMID: 20726000
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904 - 10; http://dx.doi.org/10.1016/j.ctrv.2012.04.007; PMID: 22651903
   PubMed Web of Science ®Google Scholar
• Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012; 2:722 - 35; http://dx.doi.org/10.1158/2159-8290.CD-12-0014; PMID: 22822050
   PubMed Web of Science ®Google Scholar
• Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 2012; 72:2768 - 79; http://dx.doi.org/10.1158/0008-5472.CAN-11-3567; PMID: 22472119
   PubMed Web of Science ®Google Scholar
• Bochet L, Meulle A, Imbert S, Salles B, Valet P, Muller C. Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem Biophys Res Commun 2011; 411:102 - 6; http://dx.doi.org/10.1016/j.bbrc.2011.06.101; PMID: 21712027
   PubMed Web of Science ®Google Scholar
• Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nör JE. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 2009; 11:583 - 93; PMID: 19484147
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005; 175:4338 - 46; PMID: 16177074
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206:1457 - 64; http://dx.doi.org/10.1084/jem.20090207; PMID: 19564351
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442:461 - 5; http://dx.doi.org/10.1038/nature04808; PMID: 16688182
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15:114 - 23; http://dx.doi.org/10.1016/j.ccr.2008.12.018; PMID: 19185846
   PubMed Web of Science ®Google Scholar
• Kamiya S, Okumura M, Chiba Y, Fukawa T, Nakamura C, Nimura N, et al. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett 2011; 138:47 - 53; http://dx.doi.org/10.1016/j.imlet.2011.02.022; PMID: 21453726
   PubMed Web of Science ®Google Scholar
• Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41:413 - 24; http://dx.doi.org/10.1002/eji.201040979; PMID: 21268011
   PubMed Web of Science ®Google Scholar
• Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, et al. Tumor associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 2012; 31:248 - 58; http://dx.doi.org/10.1002/stem.1281; PMID: 23169551
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314 - 21; http://dx.doi.org/10.1038/nm1325; PMID: 16288283
   PubMed Web of Science ®Google Scholar
• Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010; 70:9599 - 610; http://dx.doi.org/10.1158/0008-5472.CAN-10-1293; PMID: 21118964
   PubMed Web of Science ®Google Scholar
• Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Díaz Flaqué MC, et al. Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells. J Immunol 2012; 189:1162 - 72; http://dx.doi.org/10.4049/jimmunol.1102538; PMID: 22753933
   PubMed Web of Science ®Google Scholar
• Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, et al. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res 2012; 72:4440 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-11-3619; PMID: 22728650
   PubMed Web of Science ®Google Scholar
• Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 2010; 70:7455 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-10-0736; PMID: 20841481
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009; 27:925 - 32; http://dx.doi.org/10.1038/nbt.1564; PMID: 19749770
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2:619 - 26; http://dx.doi.org/10.1038/ncprheum0338; PMID: 17075601
   PubMedGoogle Scholar
• Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006; 66:3087 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-05-3447; PMID: 16540658
   PubMed Web of Science ®Google Scholar
• Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr., Van Veldhuizen PJ Jr., et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010; 16:3028 - 34; http://dx.doi.org/10.1158/1078-0432.CCR-09-3122; PMID: 20484019
   PubMed Web of Science ®Google Scholar
• Dave B, Landis MD, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, et al. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One 2012; 7:e30207; http://dx.doi.org/10.1371/journal.pone.0030207; PMID: 22879872
   PubMedGoogle Scholar
• Ball S, Li C, Li PK, Lin J. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One 2011; 6:e18820; http://dx.doi.org/10.1371/journal.pone.0018820; PMID: 21526200
   PubMed Web of Science ®Google Scholar
• Liu Y, Fuchs J, Li C, Lin J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle 2010; 9:3423 - 7; http://dx.doi.org/10.4161/cc.9.17.12946; PMID: 20818158
   PubMed Web of Science ®Google Scholar
• Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19:6613 - 26; http://dx.doi.org/10.1038/sj.onc.1204086; PMID: 11426647
   PubMed Web of Science ®Google Scholar
• Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2012; 2:694 - 705; http://dx.doi.org/10.1158/2159-8290.CD-12-0191; PMID: 22719020
   PubMed Web of Science ®Google Scholar
• Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008; 112:5095 - 102; http://dx.doi.org/10.1182/blood-2007-12-129718; PMID: 18824601
   PubMed Web of Science ®Google Scholar
• Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet 2011; 20:4143 - 54; http://dx.doi.org/10.1093/hmg/ddr338; PMID: 21821671
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115:3109 - 17; http://dx.doi.org/10.1182/blood-2009-04-214957; PMID: 20130243
   PubMed Web of Science ®Google Scholar
• Sun Y, Moretti L, Giacalone NJ, Schleicher S, Speirs CK, Carbone DP, et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol 2011; 6:699 - 706; http://dx.doi.org/10.1097/JTO.0b013e31820d9d11; PMID: 21325979
   PubMed Web of Science ®Google Scholar
• Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol 2012; 83:1136 - 45; http://dx.doi.org/10.1016/j.bcp.2011.12.024; PMID: 22209716
   PubMed Web of Science ®Google Scholar
• Greten FR, Karin M. Peering into the aftermath: JAKi rips STAT3 in cancer. Nat Med 2010; 16:1085 - 7; http://dx.doi.org/10.1038/nm1010-1085; PMID: 20930749
   PubMed Web of Science ®Google Scholar
• de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, et al. Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma. Oncotarget 2012; 3:1038 - 46; PMID: 23013619
   PubMedGoogle Scholar
• Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011; 9:214; http://dx.doi.org/10.1186/1479-5876-9-214; PMID: 22168571
   PubMed Web of Science ®Google Scholar